• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Palvella Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    3/31/25 7:32:24 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PVLA alert in real time by email
    8-K
    0001583648false00015836482025-03-312025-03-31

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 31, 2025

     

     

    Palvella Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Nevada

    001-37471

    30-0784346

    (State or other jurisdiction
    of incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    125 Strafford Ave, Suite 360

     

    Wayne, Pennsylvania

     

    19087

    (Address of principal executive offices)

     

    (Zip Code)

     

    Registrant’s telephone number, including area code: (484) 253-1461

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, $0.001 par value per share

     

    PVLA

     

    The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On March 31, 2025, Palvella Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 7.01 Regulation FD Disclosure.

    On March 31, 2025, the Company will hold its earnings call and use a slide presentation in conjunction with the earnings call. A copy of the presentation is furnished herewith as Exhibit 99.2, and incorporated herein by reference.

    The information furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit No.

     

    Description

    99.1

     

    Press Release of Palvella Therapeutics, Inc., dated March 31, 2025*

    99.2

     

    Earnings Call Presentation of Palvella Therapeutics, Inc., dated March 31, 2025*

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    * Furnished herewith

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Palvella Therapeutics, Inc.

     

     

     

     

    Date:

    March 31, 2025

    By:

    /s/ Matthew Korenberg

     

     

     

    Matthew Korenberg

     

     

     

    Chief Financial Officer

     


    Get the next $PVLA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PVLA

    DatePrice TargetRatingAnalyst
    4/9/2025$50.00Buy
    Chardan Capital Markets
    3/26/2025$45.00Buy
    Stifel
    3/7/2025$50.00Sector Outperform
    Scotiabank
    2/20/2025$39.00Buy
    Canaccord Genuity
    2/5/2025$44.00Buy
    TD Cowen
    12/26/2024$38.00Buy
    H.C. Wainwright
    12/18/2024Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PVLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Palvella Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $50.00

      4/9/25 7:50:47 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Palvella Therapeutics with a new price target

      Stifel initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $45.00

      3/26/25 7:50:34 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Palvella Therapeutics with a new price target

      Scotiabank initiated coverage of Palvella Therapeutics with a rating of Sector Outperform and set a new price target of $50.00

      3/7/25 8:18:07 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PVLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Wessel Tadd S.

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      6/11/25 8:00:08 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kiritsy Christopher P

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      6/11/25 7:59:56 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Jenkins George M

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      6/11/25 7:59:46 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PVLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

      WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced it has been added to the broad-market Russell 3000® Index and the Russell 2000® Index, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution. Annual Russell indexes reconstitution captures the 3,000 largest US stocks, ranking them by total market capitalization. Membership in the

      6/30/25 7:30:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

      Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies Top-line data expected in the first quarter of 2026 WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the successful completion of SELVA, a Phase 3 trial of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatme

      6/23/25 7:30:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

      New intellectual property builds on Palvella's multi-layered exclusivity strategy Patent term expected through at least 2038 WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the United States Patent and Trademark Office (USPTO) issued patent No. 12,329,748 for claims related to the Company's lead product candidate QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin

      6/18/25 7:30:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PVLA
    SEC Filings

    See more
    • Palvella Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

      6/11/25 4:05:57 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Palvella Therapeutics Inc.

      10-Q - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

      5/15/25 7:45:33 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

      5/15/25 7:31:32 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PVLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Jenkins George M bought $100,797 worth of shares (4,990 units at $20.20), increasing direct ownership by 1% to 183,171 units (SEC Form 4)

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      4/10/25 7:06:12 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Jenkins George M bought $51,720 worth of shares (4,000 units at $12.93), increasing direct ownership by 2% to 180,671 units (SEC Form 4)

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      12/19/24 10:23:28 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PVLA
    Leadership Updates

    Live Leadership Updates

    See more
    • Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

      Ms. Kline to lead Palvella's commercial buildout for planned standalone U.S. launch of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations, a serious, rare, and lifelong genetic disease affecting an estimated more than 30,0000 patients in the U.S., if approved Under Kline's leadership at Dompé, Oxervate®, a first-in-disease topical therapy for rare disease neurotrophic keratitis, scaled to over $500 million in annual U.S. sales while achieving early profitability WAYNE, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing an

      5/27/25 8:00:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PVLA
    Financials

    Live finance-specific insights

    See more
    • Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 patients; enrollment expected to close in June 2025 Phase 3 SELVA trial top-line results anticipated in the first quarter of 2026 Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for the treatment of cutaneous venous malformations top-line results on track for the fourth quarter of 2025 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs and cutaneous venous malformations Cash and cash equivalents of $75.6 million as of Ma

      5/15/25 7:30:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

      WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, May 15, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" se

      5/8/25 7:30:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

      Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs), on track for the first quarter of 2026 Top-line results from TOIVA, a Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of

      3/31/25 7:30:00 AM ET
      $LGND
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care